BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates for 2025 and beyond ahead of Q1 results due on Friday, April 25. For Q1, the firm notes that its revenue and EPS estimates are slightly higher, driven in part by modest increases in Skyrizi and Rinvoq sales. For 2025, 2026 and later 2020s, its revenue and EPS estimates remain largely in-line with prior forecasts, being 1%-2% either up or down, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves This Week, April 21 – April 25, 2025
- AbbVie Hold Rating: Modest Forecast Adjustments Amid Tariff and Pricing Concerns
- Lenz Therapeutics assumed with an Overweight at Piper Sandler
- Block, Simon, Sirius, AbbVie, Apple: Trending by Analysts
- Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP